New drug NRM-823 takes on Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage study tests a new drug, NRM-823, alone or with an immunotherapy, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety and find the right dose. About 150 adults with cancers like lung, ovarian, or tri…
Phase: PHASE1 • Sponsor: Normunity AccelCo, Inc. • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC